The U.S. Trade Representative has announced that it is proposing a 25% tariff on approximately 1,300 categories of products imported from China. A public notice and comment process, as well as a hearing, will be conducted to review the USTR’s proposed list, which includes numerous goods imported by pharmaceutical and medical device manufacturers. We recommend that effected parties submit comments to voice their concerns.
On April 3, 2018, the U.S. Trade Representative (USTR) published a list of products imported from China that it recommends be subject to a 25% tariff. The list includes numerous goods essential to U.S. manufacturing and technology industries. The USTR has proposed this tariff pursuant to an investigation conducted under section 301 of the Trade Act of 1974, as amended (19 U.S.C. § 2411), which authorizes the President to unilaterally impose restrictions against countries that violate trade agreements, or that engage in acts, policies or practices that are unreasonable or discriminatory and burden or restrict the United States.